H1 Blog

NOVEMBER 15, 2023

For more information on how to build effective and compliant engagement plans, download our white paper: How AI Can Save Medical Affairs from Drowning in Data. It is a vital component in building trust and maintaining ethical standards in the healthcare industry.

Compliance 59

Compliance Science Regulations Pharmaceutical Companies 59

The Pharma Data

NOVEMBER 20, 2020

Pharma leaders fear extreme vulnerability in end-to-end supply chain as pandemic continues, according to global survey. Explore how pharma companies and industry leaders can reset for growth in the lab beyond coronavirus in Pharma IQ ’s fourth annual edition of Smart Lab Digital. Save your early bird seat now.

Pharma Companies 52

Pharma Companies Vaccine Pharmacy Drugs 52

PerkinElmer

FEBRUARY 18, 2021

Eckelt conducted 23 hour-long, 1:1 interviews over five months in 2020 to gather market insights on how the top 20 Pharma are increasing productivity, efficiency, and speed of drug discovery in the short and long-term. A PerkinElmer White Paper offers a detailed look at the findings.

Biochemical Assays 52

Biochemical Assays Drugs Small Molecule Pharma Companies 52

The Pharma Data

SEPTEMBER 11, 2020

In an effort to slow the spread of the disease and prevent a second wave, pharma companies around the world are continuously looking to advance new methods of treatment. This week’s round up dives into developments from companies based in Australia and the US. “The

Clinical Trials 52

Clinical Trials Pharma Companies Hospitals Trials 52

The Pharma Data

OCTOBER 16, 2020

As pharma companies search for solutions to avoid cancelling or delaying clinical trials, virtualizing trials are fast becoming commonplace during the Covid-19 pandemic. Download Medidata’s white paper to learn how to virtualize clinical trials and bring new therapies closer to patients. Source link.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Clinical Research 52

Drug Discovery World

SEPTEMBER 29, 2022

Outsourcing can alleviate unnecessary backlogs and provide access to cutting-edge technologies, giving companies an edge to reach critical discovery milestones in a timely manner. Big pharma companies routinely maintain their own decks of upwards of millions of compounds.

Small Molecule 130

Small Molecule Assay Development DNA Biochemical Assays 130